Immunovant, Inc. Common Stock (IMVT) is a publicly traded Healthcare sector company. As of November 9, 2026, IMVT trades at $33.42 with a market cap of $6.31B and a P/E ratio of -12.14. IMVT moved +9.45% today. Year to date, IMVT is +17.83%; over the trailing twelve months it is +28.98%. Its 52-week range spans $12.72 to $45.42. Analyst consensus is buy with an average price target of $48.22. Rallies surfaces IMVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immunovant Q2 loss narrows to $97.25 million; IMVT-1402 meets rheumatoid arthritis endpoint: Immunovant’s fiscal second-quarter net loss narrowed 23% year over year to $97.25 million, or $0.47 per basic share, versus analyst expectations for a $152.92 million loss. IMVT-1402 met the primary endpoint in difficult-to-treat rheumatoid arthritis, with topline data from Graves’ disease and myasthenia gravis trials expected in 2027.
| Metric | Value |
|---|---|
| Price | $33.42 |
| Market Cap | $6.31B |
| P/E Ratio | -12.14 |
| EPS | $-2.77 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.42 |
| 52-Week Low | $12.72 |
| Volume | 61.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-505.61M |
| Gross Margin | 0.00% |
10 analysts cover IMVT: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $48.22.